Hereditary Angioedema
Astria Therapeutics Inc. focuses its clinical research on hereditary angioedema, with studies spanning both Type 1 and Type 2 HAE. The programme centers on preventing attacks and evaluating treatment options for people living with this rare disease.
- Attack prevention in hereditary angioedema
- Type 1 and Type 2 HAE
- Adult and adolescent populations
The sponsor’s current trial portfolio includes multiple active studies across several countries, with research sites supporting the clinical evaluation of HAE in both long-term and preventive care settings.
Long-term Safety and Tolerability
One major area of interest is the long-term safety and tolerability of investigational therapies for hereditary angioedema. These studies examine sustained treatment use in adults and adolescents, with attention to ongoing treatment exposure over time.
- Long-term treatment safety
- Tolerability in repeated use
- Chronic management of HAE
This focus reflects a therapeutic emphasis on maintaining control of angioedema attacks while monitoring how therapies are received in routine preventive use.
Preventive Therapy Development
The sponsor is actively involved in research on preventive treatment for hereditary angioedema, including evaluation of therapies intended to reduce the frequency of attacks. This includes studies in adults as well as adolescents with HAE.
- Prophylaxis for HAE attacks
- Adult preventive treatment
- Adolescent treatment evaluation
These trials support the development of subcutaneous treatment approaches for people needing ongoing protection from recurrent hereditary angioedema episodes.
